Loading...
In the manufacturer-funded ExTRACT-TIMI 25 trial, enoxaparin administered for 7 days was a better adjunct to fibrinolysis than was unfractionated heparin (UFH) administered for 48 hours (Journal Watch Cardiology Apr 6 2006). In this prospective subanalysis, investigators analyzed results in 4676 patients who subsequently underwent percutaneous coronary intervention within 30 days.
Patients who received enoxaparin required PCI slightly less frequently (23% vs. 24%, P=0.027) and slightly later (122 hours vs. 109 hours, P=0.006) than patients who received UFH, owing to a delay in recurrence of ischemia or MI. The primary endpoint of death or MI by 30 days after fibrinolysis occurred in a smaller percentage of PCI patients who received enoxapari…